Novel Noninvasive Biosensors and Artificial Intelligence for Optimized Heart Failure Management

Luke Neill*, Mozziyar Etemadi, Liviu Klein, Omer T. Inan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)316-318
Number of pages3
JournalJACC: Basic to Translational Science
Volume7
Issue number3P2
DOIs
StatePublished - Mar 2022

Funding

Dr Neill has an equity stake in Cardiosense, Inc; and is an employee of Cardiosense. Dr Etemadi is a cofounder, board member, and advisor for Cardiosense, Inc; and has an equity stake in Cardiosense. Dr Inan is a scientific advisor for Physiowave, Inc; a cofounder, board member, and scientific advisor for Cardiosense, Inc; has an equity stake in Cardiosense; is a cofounder, board member, and scientific advisor for Arthroba, Inc; has an equity stake in Arthroba, Inc; has received research funding for his lab from Hillrom, Inc and Cisco, Inc; and has intellectual property licensed by Physiowave, TandemLaunch, and Cardiosense. Dr Klein has an equity stake in Cardiosense, Inc; and is a clinical advisor for Cardiosense.

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this